In March 2025, Zydus Lifesciences entered into agreements with PAI and two minority shareholders of Amplitude Surgical to acquire blocks of shares representing in aggregate 85.6% of Amplitude Surgical’s share capital and voting rights at a price of €6.25 per share and a total consideration of €256.8 million.
As all conditions precedent to the completion have now been fulfilled, and the Block Acquisition has been subsequently completed on July 29, 2025, Zydus now holds 85.6% of the share capital and voting rights of Amplitude Surgical.
Olivier Jallabert will remain in his role as CEO of Amplitude Surgical.
Zydus will file a simplified mandatory tender offer on July 30, 2025 for all the remaining outstanding shares of Amplitude Surgical at a price of €6.25 per share.
Zydus discovers, develops, manufactures and markets a broad range of healthcare therapies. Amplitude Surgical is a French player in the global market for surgical technologies for lower limb orthopaedics, and develops and markets high-end products for orthopaedic surgery, covering the main pathologies affecting the hip and knee. .
In March 2025, Zydus Lifesciences entered into agreements with PAI and two minority shareholders of Amplitude Surgical to acquire blocks of shares representing in aggregate 85.6% of Amplitude Surgical’s share capital and voting rights at a price of €6.25 per share and a total consideration of €256.8 million.
As all conditions precedent to...
In March 2025, Zydus Lifesciences entered into agreements with PAI and two minority shareholders of Amplitude Surgical to acquire blocks of shares representing in aggregate 85.6% of Amplitude Surgical’s share capital and voting rights at a price of €6.25 per share and a total consideration of €256.8 million.
As all conditions precedent to the completion have now been fulfilled, and the Block Acquisition has been subsequently completed on July 29, 2025, Zydus now holds 85.6% of the share capital and voting rights of Amplitude Surgical.
Olivier Jallabert will remain in his role as CEO of Amplitude Surgical.
Zydus will file a simplified mandatory tender offer on July 30, 2025 for all the remaining outstanding shares of Amplitude Surgical at a price of €6.25 per share.
Zydus discovers, develops, manufactures and markets a broad range of healthcare therapies. Amplitude Surgical is a French player in the global market for surgical technologies for lower limb orthopaedics, and develops and markets high-end products for orthopaedic surgery, covering the main pathologies affecting the hip and knee. .
Copy to clipboard 
